Bafna Pharmaceuticals Ltd vs Cipla Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 138.4 as of 04 May 11:20 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Cipla Ltd changed from 27.3 on March 2021 to 22.1 on March 2025 . This represents a CAGR of -4.14% over 5 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Cipla Ltd changed from ₹ 65746 crore on March 2021 to ₹ 116434 crore on March 2025 . This represents a CAGR of 12.11% over 5 years The revenue of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Cipla Ltd for the Dec '25 is ₹ 7280 crore as compare to the Sep '25 revenue of ₹ 7858 crore. This represent the decline of -7.35% The ebitda of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Cipla Ltd for the Dec '25 is ₹ 1185 crore as compare to the Sep '25 ebitda of ₹ 2163 crore. This represent the decline of -45.21% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Cipla Ltd changed from ₹ 1176 crore to ₹ 674.56 crore over 7 quarters. This represents a CAGR of -27.22% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Cipla Ltd changed from 16.34 % on March 2021 to 25.05 % on March 2025 . This represents a CAGR of 8.92% over 5 years .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About Cipla Ltd

Cipla Limited is one of the leading pharmaceutical companies in India.
The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and Cipla Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Cipla Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 321 Cr while Market cap of Cipla Ltd is 105,811 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Cipla Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and Cipla Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and Cipla Ltd?

As of May 4, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹135.7. On the other hand, Cipla Ltd stock price is INR ₹1309.9.

How do dividend payouts of Bafna Pharmaceuticals Ltd and Cipla Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Cipla Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.